The never-ending fight against cancer has been going on for decades. This deadly disease has claimed the lives of millions of people on a worldwide scale. Fortunately, all is not lost because there has been many breakthroughs over the past few years. Cancer Treatment Centers of America is leading this valiant charge, and it has revolutionized patient-centered care. No two cancer patients are the same and no two cancers are the same. This is why Cancer Treatment Centers of America is so special, and the organization has teamed-up with WebMD to provide a plethora of informative-information for cancer patients.
This partnership is on a mega-scale, and it allows individuals to navigate the cancer experience. This experience includes diagnosis, survivorship, treatment and caregiver information. The entire gambit is being covered here. Since there is a wide variety of cancers, the partnership between the two giants offer a ton of information that spans across each cancer topic such as breast, colon, lung, prostate and skin. This is one of the best interactive-approaches of the 21st century and the platform is very user-friendly. Cancer Treatment Centers of America has been around since the late 1980s, and it has been providing high-quality, personalized medicines to cancer patients. The organization has a long list of happy survivors as well as an extensive resume of success, and Twitter.com.
Atlanta, Phoenix, Chicago, Tulsa and Philadelphia are where the main hospitals are located. Some of the most state-of-the-art technologies are used here. The clinical staff is made-up of extraordinary nurses and oncologists, and these professionals work directly with each patient. Cancer Treatment Centers of America is on another level, especially when compared to its counterparts. All in all, this organization has set new trends, has helped to raise the bar higher than before and is changing the current status quo, and https://angel.co/cancer-centers.
Markets Insider’s article provided by PR Newswire, details the latest collaboration between Cancer Treatment Centers of America and Pacira Pharmaceutical, Inc. called the Opioid Risk Reduction Initiative. The Opioid Risk Reduction Initiative was created to reduce the possibility of opioid dependence for cancer patients, who often had multiple exposures to narcotics as post-surgical pain management treatment. The initiative seeks to educate patients and oncologists both on the responsible use of opioids while simultaneously providing information on opioid alternatives. The initiative seeks to improve the pain management options.As Neil Seeley, the Chief of the Division of Anesthesia at Cancer Treatment Centers of America, reveals, narcotics have traditionally been at the heart of pain treatment for post-surgical pain management.
Clinicians believed it was safe and would not cause dependence, which they are discovering is not necessarily true for all patients. The collaboration reveals the risks of extended narcotic use, helping to highlight the opioid alternatives for pain management while relegating opioids to a supportive role. The goals of the Opioid Risk Initiative include educating cancer patients about the effective opioid alternatives and responsible use, to educate the medical community about the alternatives while enhancing the recovery process and relieving potential opioid misuse and addition, and creating a procedure of non-opioid pain support protocols.
Cancer Treatment Centers of America is a fully accredited national network of hospitals which specialize in cancer treatment. Each patient is provided with an expert team of doctors and clinicians to help provide support and information on the diagnosis and treatment needs. The integrative treatment plan is created through precision medicine, tailored specifically to the needs of the patient. Cancer Treatment Centers of America goes beyond just diagnosis and treatment, they also provide a collaborative approach through innovative treatment options and therapies. They use a multidisciplinary team to create an integrated treatment plan to help each patient maintain their energy, manage side effects and pain, and remain strong emotionally and physically throughout treatment and recovery.
Clay Siegall has an enviable reputation within the scientific community. This is because he is constantly advocating for further research on cancer treatment. His aim is to eventually find a cure for this illness. Clay Siegall is adequately qualified in doing this job. He has earned a high end doctorate degree.
Now he is focused on practicing all that has learned in medical school. This is why Clay Siegall has formed a conglomerate with other like-minded scientists. This was in 1998. This is how Seattle Genetics was created. This is a company that is dedicated to research in order to create new and viable treatments for cancer. This company has been valuable in this search for treatment of cancer.
He is quite active on Facebook. His posts show that he is focus driven. Most of his posts are about his work, denoting the passion that he has for it.
The website of Seattle Genetics states its purpose very clearly. They are trying to find a cure for the debilitating disease called cancer. They are focusing on finding new anti-bodies that are powerful enough to defeat cancer.
In fact, Clay Siegall is not trying to combat this disease along. He and his colleagues have got into strong alliances with many pharmaceutical corporations in order to come up with effective solutions.
These companies include Pfizer, Genetech and many others. Such alliances show how committed Clay Siegall is towards destroying this disease completely.
This kind of effort made in research along with possible distribution of more effective, new and stronger drugs may lead to the end of cancer. This is the only way to bring hope to the dark lives of many people who are suffering from this disease.
This work on cancer research has made Clay Siegall an experienced scientist as well as expert in this field. This also indicates that he is a humanitarian who is dedicated towards making positive changes in the lives of people. His research is going to have a positive impact on a number of lives. People will be thanking him for years to come!
Clay Siegall has dedicated his life to finding cures for cancers. He obtained his Ph.D. in Genetics and worked in the pharmaceutical and cancer research industries until he founded his company, Seattle Genetics. Siegall and his company were recently profiled in an article published by the Puget Sound Business Journal.
Seattle Genetics has great hopes for its commercialized drug, Adcetris, which is being tested in trials combating different types of lymphomas. Adcetris, in 2015, had earned the company $226 million in the United States of America and Canada. This year sales are expected to be in a similar range. The partner of Seattle Genetics is Takeda Pharmaceutical which sells the drug in other countries. Siegall is testing 12 additional drugs the company has developed. Seattle Genetics is expanding and is begginng a hiring campaign at its Seattle location. The company plans on hiring 100 additional employees in the U.S. and 20 additional hires at its facility in Switzerland. Seattle genetics currently has more than 800 employees.
Clay Siegall’s sense of dedication should be a model to all Americans. He has proven that with determination and study an individual can achieve great results that benefit mankind. Certainly, the discovery of a single cancer remedy is of great importance. Siegall knew at an early age that science was the direction for his life and cancer research was his intended area of study and work. If funds for the sciences were more readily available in high school programs and schools could concentrate more on science education rather than satisfying those parents promoting pseudo-science creation myths, we would be further along in our quest to improve everyone’s health and lives.
A country is only as good as the people we send into the workforce who want to improve our lives through scientific endeavors. We should not be a society only out to get the most money, the biggest house, and the fastest car for ourselves, but a society that wants to discover scientific truths to improve our fragile world.
Mirna Therapeutics is an up and coming biotechnology company that was founded in 2007. The company has recently appointed Dr. Clay Siegall to its Board of Directors. Dr. Clay Siegall is a strong addition to Mirna Therapeutics as he has had extensive success in the field of biotechnology as co-founder and CEO of Seattle Genetics. Dr. Clay Siegall co-founded Seattle Genetics in 1998 and has since served on the Board of Directors of Ultragenyx Pharmaceutical,Alder BioPharmaceuticals, and Washington Roundtable. Under his direction and leadership Seattle Genetics released their first commercial product, ADCETRIS (brentuximab bedroom) in 2011. Dr. Clay Siegall was also very successful with capital-raising activities for Seattle Genetics. Through his efforts he secured $675 million in public and private financing for the company.
Mirna Therapeutics Inc. Appoints Clay B. Siegall, Ph.D., to Its Board of Directors
Mirna Therapeutics is similar to Seattle Genetics in that it’s focus is to develop and commercialize innovative therapies in oncology and disease. Unlike Seattle Genetics which focuses on antibody-based therapies; Mirna Therapeutics focuses specifically on the development of microRNA (miRNA) therapeutics. The use of miRNA therapeutics for tumor suppression and as anti-cancer agents is promising. The most heavily researched miRNA, miR-34, has been shown to affect pathways and processes critical to cancer cell viability. As pre-clinical animal trials have shown that miR-34 blocks tumor growth, Mirna Therapeutics has designed their current treatment product MRX34 to mimic miR-34. As of this year the first phase of clinical trials for MRX34 have begun. Patients participating in the trial include those diagnosed with primary liver cancer, advanced solid tumors, and hematological malignancies.
At the forefront of precision research in the medical field is the Rutgers institute. Situated in New Jersey, this institution focuses majority of its resources and intellectual effort in providing answers to the modern day problem of cancer. This exercise calls for nothing but top standard and highly motivated scholars in order to propel the groundbreaking medical innovation. In a bid to sustain the required unique level of commitment, discipline, support and hence progression, a total of 18chairs had to be created. The ambition in this was to attract anonymous donations of $1.5 million from each chair. Having pledged $1.5 million, Omar Boraie the New Brunswick developer had the privilege of having the chair named for him.
After several years of research in this field with few substantial breakthroughs, genomic science has embarked on making changes to the line of approach used in the research work. Precision medicine has also had a major to play in the shifting ways that professionals and experts as well carry out diagnosis and treatment of cancer cases. Unlike in the past, recent procedure for handling cancerous tumors is up on the genes and genetic composition of the specimen in question. This has enabled the provision of custom-made solutions for each person hence improving on the effectiveness of the remedies. The works of precision medicine have been so promising for the future that at a recent address to the state, president Obama promised further initiative support.
Despite the fact that numerous other centers have subscribed to the use of genes to remedy cancer situations, none has been able to incorporate the use of precision medicine like the Rutgers cancer institution. Genomic sequencing generally greatly improves the chances of effective therapy especially for the unique cases of cancer in the community. This development has been very essential in the classification of various cancers into subcategories.
Due to the tenacious work of the researchers in this line of work, the treatment of non-responsive cancer cases is possible. The pledge made by Omar Boraie has been very essential in leveraging support for the program. With more 17 pledges that are to be made, it is expected that research work intensify for betterment of results in healthcare and facilitation of cancer patients.
The Rutgers institution is leading the way with this work. It was one of the very first organizations in the state. It also works hand in hand with the state university of New Jersey to ensure steady supply of tenacious and motivated intellectuals in the system. The facilitation of translational research has also been a very crucial part of healthcare in the state.